RxDoctor Payments Data

Sylvia Klineova, MD

Neurology · New York, NYNPI 1053572859

Payments from drug & device makers

$785,548in general payments, 2019–2025

Across 313 payments — averaging $2509.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$399K
  • Roche Products Limited$145K
  • Adamas Pharmaceuticals, Inc.$62K
  • Hoffmann-la Roche Limited$60K
  • AstraZeneca$39K
  • F. Hoffmann-la Roche AG$24K
  • plus $56K from 7 others

What the payments were for

  • Consulting fees$73,71232%
  • Speaking & faculty fees$133,37058%
  • Travel & lodging$16,7997%
  • Food & beverage$4,9672%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$785,548 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$30,514
Medicare patients
161
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab24$198,246
Avonex (4 Pack)Interferon Beta-1a15$118,822
Plegridy PenPeginterferon Beta-1a11$89,466
Dimethyl Fumarate26$72,295
Glatiramer Acetate33$59,167
Teriflunomide12$43,710
Dalfampridine ErDalfampridine50$11,697
Carbamazepine ErCarbamazepine17$1,873
Pregabalin20$1,694
Oxybutynin Chloride ErOxybutynin Chloride57$1,481
Mycophenolate Mofetil19$1,293
Baclofen48$749
Gabapentin36$517
Oxcarbazepine30$507
Levetiracetam11$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$399,023$118,82215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →